Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;41(7):1003-1022.
doi: 10.1007/s10096-020-04121-1. Epub 2021 Jan 5.

Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

Sajad Yaghoubi  1 , Angelina Olegovna Zekiy  2 , Marcela Krutova  3 , Mehrdad Gholami  4 , Ebrahim Kouhsari  5   6 , Mohammad Sholeh  7 , Zahra Ghafouri  8 , Farajolah Maleki  9
Affiliations
Review

Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

Sajad Yaghoubi et al. Eur J Clin Microbiol Infect Dis. 2022 Jul.

Abstract

Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the treatment of polymicrobial infections caused by multidrug-resistant Gram-positive and Gram-negative pathogens. Tigecycline evades the main tetracycline resistance genetic mechanisms, such as tetracycline-specific efflux pump acquisition and ribosomal protection, via the addition of a glycyclamide moiety to the 9-position of minocycline. The use of the parenteral form of tigecycline is approved for complicated skin and skin structure infections (excluding diabetes foot infection), complicated intra-abdominal infections, and community-acquired bacterial pneumonia in adults. New evidence also suggests the effectiveness of tigecycline for the treatment of severe Clostridioides difficile infections. Tigecycline showed in vitro susceptibility to Coxiella spp., Rickettsia spp., and multidrug-resistant Neisseria gonnorrhoeae strains which indicate the possible use of tigecycline in the treatment of infections caused by these pathogens. Except for intrinsic, or often reported resistance in some Gram-negatives, tigecycline is effective against a wide range of multidrug-resistant nosocomial pathogens. Herein, we summarize the currently available data on tigecycline pharmacokinetics and pharmacodynamics, its mechanism of action, the epidemiology of tigecycline resistance, and its clinical effectiveness.

Keywords: Tigecycline antibacterial activity; Tigecycline clinical Effectiveness; Tigecycline resistance.

PubMed Disclaimer

Conflict of interest statement

Authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Tigecycline mechanisms of action and resistance
See this image and copyright information in PMC

References

    1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and therapeutics. 2015;40(4):277. - PMC - PubMed
    1. Tasina E, Haidich A-B, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11(11):834–844. doi: 10.1016/S1473-3099(11)70177-3. - DOI - PubMed
    1. Guay DR. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2004;24(1):58–68. doi: 10.1592/phco.24.1.58.34808. - DOI - PubMed
    1. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331–336. doi: 10.1016/j.diagmicrobio.2012.12.004. - DOI - PubMed
    1. FDA U FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections (1 September 2010).

MeSH terms